Shots: The P-III PARAGON-HF study involves assessing of Entresto vs valsartan in 4,822 HF patients with preserved ejection fraction, resulted in 13% reduction in HF hospitalization and CV death, 15% […]readmore
Tags : Novartis
Shots: The P-III ASCLEPIOS I and II (NCT02792218 and NCT02792231) studies involve assessing of Ofatumumab (20mg, SC, monthly) vs Aubagio (teriflunomide, 14mg, qd) in 1,882 patients with MS aged 18-55yrs. […]readmore
OxThera’s Oxabact Receives EMA’s Positive Decision on Pediatric Investigational Plan to Treat Primary Hyperoxaluria Published: Aug 23, 2019 | Tags: OxThera, Oxabact, Receives, EMA, Positive Decision, Pediatric Investigational Plan, Treat, Primary […]readmore
Healthcare, pharmaceutical, and biotech companies are gearing up to tap new markets as they look to consolidate their positions after a spate of mergers & acquisitions and licensing partnerships in […]readmore
Shots: Novartis to get an option on Iconic’s ophthalmology program in exchange for an up front payment and equity investment in Iconic Iconic is evaluating its anti-Tissue Factor monoclonal antibody, […]readmore
Shots: Novartis to receive $20M (€17.9M) up front, regulatory and commercial milestones plus royalties on sales. Pharming to get exclusive rights to develop and commercialize Novartis’ CDZ173 (leniolisib). Additionally, Pharming […]readmore
The increasing cases of autoimmune disorders such as rheumatoid arthritis are driving the growth of immunology products in the global market. Multiple companies have been focusing on Oncology, Hematology and […]readmore
Shots: The P-III MONALEESA-3 study involves assessing of Kisqali (ribociclib) + fulvestrant in postmenopausal women with HR+/HER2- advanced or m-breast cancer The second phase of P-III MONALEESA-3 study resulted in meeting […]readmore
Shots: The EMA’s CHMP has recommended the approval of Lucentis (ranibizumab, 10 mg/ml) for the treatment of ROP in preterm infants with EC’s anticipated decision within three months The submission […]readmore
Shots: Novartis to receive up front and up to $291M upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. Gilead acquires exclusive WW […]readmore